Evidence map›Paper›PMID 34453499›Full record

ArticleThoracic cancer2021

A novel lncRNA-miRNA-mRNA competing endogenous RNA regulatory network in lung adenocarcinoma and kidney renal papillary cell carcinoma.

Qiwei Zhou, Diangeng Li, Hongying Zheng, Zheng He, Feng Qian, Xiaotian Wu, Zhiwei Yin, Peng Tao Bao, Meiling Jin

Open access · goldAbstract read
In one paragraph

Article in Thoracic cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Current issues in molecular biology · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 2 countries.

Qiwei ZhouDepartment of Urology, Chinese People's Liberation Army General Hospital/PLA Medical School, Beijing, China.
Diangeng LiDepartment of Scientific Research, Beijing-Chaoyang Hospital, Beijing, China.
Hongying ZhengHarbin Medical University, Ha'erbin, China.
Zheng HeDepartment of Laboratory, Chinese People's Liberation Army General Hospital, Beijing, China.
Feng QianDepartment of Emergency Medicine, Chinese People's Liberation Army No. 92493 Hospital, Huludao, China.
Xiaotian WuCollege of Integration Science, Yanbian University, Yanbian, China.
Zhiwei YinDepartment of Nephrology, Chinese People's Liberation Army General Hospital, Chinese People's Liberation Army Institute of Nephrology, State Key Laboratory of Kidney Diseases (2011DAV00088), National Clinical Research Center for Kidney Diseases, Beijing, China.
Peng Tao BaoDepartment of Respiratory Medicine, The Eighth Medical Center of Chinese People's Liberation Army General Hospital, Beijing, China.
Meiling JinDepartment of Nephrology, Chinese People's Liberation Army General Hospital, Chinese People's Liberation Army Institute of Nephrology, State Key Laboratory of Kidney Diseases (2011DAV00088), National Clinical Research Center for Kidney Diseases, Beijing, China.ORCID 0000-0002-0093-0377
Chinese PLA General Hospital · CNPeople's Liberation Army No. 150 Hospital · CNBeijing Chaoyang Emergency Medical Center · CNChinese General Hospital College of Nursing and Liberal Arts · PHChinese People 's Liberation Army No. 85 Hospital · CNHarbin Medical University · CNYanbian University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGPRIN1 may be a novel tumor regulator, but its role and mechanism in tumors are still unclear.

methodsFirst, a pan-cancer correlation analysis was conducted on the expression and prognosis of GPRIN1 based on the data downloaded from The Cancer Genome Atlas (TCGA) database. Second, the Starbase database was used to predict the upstream miRNAs and lncRNAs of GPRIN1, and the expression analysis, survival analysis, and correlation analysis were performed to screen the microRNA (miRNAs)/long non-coding RNAs (lncRNAs) that had a correlation with kidney renal papillary cell carcinoma (KIRP) or lung adenocarcinoma (LUAD). Third, the CIBERSORT algorithm was employed to calculate the proportion of various types of immune cells, and then the R packages were used for evaluating the relation between GPRIN1 expression and tumor immune cell infiltration as well as between GPRIN1 and the immune cell biomarker. Finally, the correlation analysis was made on GPRIN1 and immune checkpoints (CD274, CTLA4, and PDCD1).

resultsThe pan-cancer analysis suggested that GPRIN1 was up-expressed in KIRP and LUAD, and it correlated with poor prognosis. LINC00894/MMP25-AS1/SNHG1/LINC02298/MIR193BHG-miR-140-3p was likely to be the most promising upstream regulation pathway of GPRIN1. Upexpression of LINC00894/MMP25-AS1/SNHG1/LINC02298/MIR193BHG and downexpression of miR-140-3p were found relevant with poor outcomes of KIRP and LUAD. GPRIN1 expression was significantly correlated with tumor immune cell infiltration, immune cell biomarkers, and immune checkpoints.

conclusionsThe competitive endogenous (ceRNA) of miR-140-3p-GPRIN1 axis and its upstream lncRNAs are closely related to KIRP and LUAD, and might affect the prognosis and therapeutic effect of KIRP and LUAD.

Indexed as

Adenocarcinoma of LungCarcinoma, Renal CellGene Expression Regulation, NeoplasticHumansKidney NeoplasmsLung NeoplasmsMicroRNAsNerve Tissue ProteinsReceptors, N-Methyl-D-AspartateRNA, Long NoncodingGRIN1 protein, humanMicroRNAsMirn140 microRNA, humanNerve Tissue ProteinsReceptors, N-Methyl-D-AspartateRNA, Long Noncodingcompeting endogenous RNAsGPRIN1Kidney renal papillary cell carcinomaLung adenocarcinomamiR-140-3p

Identifiers

PMID34453499
PMCPMC8487820
OpenAlexW3195722703

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.